NCT04640181View on ClinicalTrials.gov

Factor Xa Inhibitor Versus Standard of Care Heparin in Hospitalized Patients With COVID-19 (XACT)

PHASE2CompletedINTERVENTIONAL
Enrollment

150

Participants

Timeline

Start Date

December 1, 2020

Primary Completion Date

June 28, 2021

Study Completion Date

June 28, 2021

Conditions
Covid19
Interventions
DRUG

Enoxaparin

Subcutaneous enoxaparin While hospitalized only.

DRUG

Rivaroxaban

Oral rivaroxaban While hospitalized and through discharge for a total of 28 days.

Trial Locations (1)

78705

St. David's Medical Center, Austin

All Listed Sponsors
lead

St. David's HealthCare

OTHER

NCT04640181 - Factor Xa Inhibitor Versus Standard of Care Heparin in Hospitalized Patients With COVID-19 (XACT) | Biotech Hunter | Biotech Hunter